Ibsrela

Active Ingredient(s): Tenapanor Hydrochloride
FDA Approved: * September 12, 2019
Pharm Company: * ARDELYX INC
Category: Hyperphosphatemia

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ibsrela Overview

Tenapanor is a drug developed by Ardelyx, which acts as an inhibitor of the sodium-proton exchanger NHE3. This antiporter protein is found in the kidney and intestines, and normally acts to regulate the levels of sodium absorbed and secreted by the body. When administered orally, tenapanor selectively inhibits sodium uptake in the intestines, limiting the amount absorbed from food, and thereby reduces levels of sodium in the body.[1] This may make it useful in the treatment of...

Read more Ibsrela Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tenapanor

Recent Ibsrela Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tenapanor Hydrochloride
  • Tablet: 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ibsrela: (1 result)

Sorted by National Drug Code
  • 73154-050 Ibsrela 53.2 mg Oral Tablet by Ardelyx, Inc.

Other drugs which contain Tenapanor Hydrochloride or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 11 November 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA